enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. First participants randomized in AskBio Phase II gene therapy ...

   lite.aol.com/tech/story/0022/20250114/9331631.htm

   Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Enrollment ongoing in the United States for REGENERATE-PD clinical trial of AB-1005 (also known as AAV2-GDNF) glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy for the treatment of moderate-stage Parkinson’s disease

3. Hope for Parkinson’s disease symptoms is found in ... - AOL

   www.aol.com/finance/hope-parkinson-disease...

   Parkinson’s disease, which is lifelong, progressive, and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the ...

4. Management of Parkinson's disease - Wikipedia

   en.wikipedia.org/wiki/Management_of_Parkinson's...

   In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...

5. Gene therapy in Parkinson's disease - Wikipedia

   en.wikipedia.org/wiki/Gene_therapy_in_Parkinson's...

   However, with this treatment, the number of substantia nigra neurons decrease so it becomes less efficient. [2] These treatments try to reduce the symptoms of the patient focusing on increasing the production of dopamine but they do not cure the disease. The new treatments for PD are in clinical trials and most of them are centered on gene therapy.

6. Prasinezumab - Wikipedia

   en.wikipedia.org/wiki/Prasinezumab

   Prasinezumab (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.

7. Michael J. Fox says he doesn’t expect a Parkinson’s cure in ...

   www.aol.com/news/michael-j-fox-parkinsons...

   “I’m really blunt with people about cures," he says in a new interview. "When they ask me if I will be relieved of Parkinson’s in my lifetime, I say, ‘I’m 60 years old, and science is ...